Ramucirumab,Therapeutic Antibodies,DC Chemicals

Cas No.:	947687-13-0
pH value:	Corresponds to reference standard： PASS
Non-reduced CE-SDS:	98.2%
SEC-HPLC:	99.5%
Isoelectric Point:	Corresponds to reference standard:PASS
Bacterial Endotoxins Test:	＜1 EU/ml
Exogenous Residual DNA:	1 pg/mg
Residual protein A:	＜1 ng/mg
Biological Activity:	Compared with standard, the range of biological activity is 107%
Osmolality:	Corresponds to reference standard: PASS
Peptide mapping:	Corresponds to reference standard: PASS
N-terminal sequence:	Corresponds to reference standard:PASS

Description:	Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors[1]. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D[2].
Target:	VEGFR-2
References:	[1]. Fala L. Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non-Small-Cell Lung Cancer. Am Health Drug Benefits. 2015 Mar;8(Spec Feature):49-53. [2]. Oholendt AL, et al. Ramucirumab: A New Therapy for Advanced Gastric Cancer. J Adv Pract Oncol. 2015 Jan-Feb;6(1):71-5.

Cat. No.	Product name	Field of application
A1087	Enfortumab vedotin-ejfv	Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma.
A1086	Lorvotuzumab-MMAE
A1085	Lifastuzumab vedotin	Lifastuzumab vedotin (RG-7599; DNIB0600A) is an antibody-drug conjugate (ADC) that comprises a humanized IgG1 anti-NaPi2b monoclonal antibody (MNIB2126A) and a potent antimitotic agent, monomethyl auristatin E (MMAE), which inhibits cell division by blocking the polymerization of tubulin. Lifastuzumab vedotin has the potential for non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (PROC) research.
A1084	Sofituzumab Vedotin	Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer.
A1083	Oregovomab-MMAE
A1082	Ensituximab-MMAE
A1081	Anetumab-MMAE	Anetumab-MMAE is an antibody-drug conjugate (ADC) (Anetumab antibody (HY-P99352), Linker: VC linker, Payload: MMAE (HY-15162)). Anetumab is an anti-mesothelin (MSLN) antibody.
A1080	Talacotuzumab-MMAE
A1079	Lonigutamab-MMAE
A1078	Glembatumumab vedotin	Glembatumumab vedotin (CDX-011) is an ADC comprising a fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB) and conjugated to the potent tubulinbinding cytotoxic agent MMAE via a protease-sensitive vc linker. Glembatumumab vedotin has potent anticancer effects.